Study of Marstacimab in Men With Hemophilia
A Multicenter, Open-Label, Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of Subcutaneous or Intravenous PF-06741086 in Subjects With Severe Hemophilia
Category & Conditions: Rare Diseases
Medicine: marstacimab (PF-06741086)
ClinicalTrials.gov Identifier (NCT): NCT02974855
Protocol ID: B7841002
PrintDownloadOpen Plain Language Summary Result: Click here